Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2b randomized, double-blind, placebo-controlled study evaluating the safety
and efficacy of elagolix alone and in combination with add-back therapy versus placebo on
heavy menstrual bleeding in premenopausal women 18 to 51 years of age with uterine fibroids.